Galapagos マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Paul Stoffels

最高経営責任者

€2.0m

報酬総額

CEO給与比率	38.0%
CEO在任期間	2.6yrs
CEOの所有権	n/a
経営陣の平均在職期間	2.5yrs
取締役会の平均在任期間	2.6yrs

経営陣の近況

Recent updates

CEO報酬分析

Galapagos の収益と比較して、Paul Stoffels の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-€61m
Jun 30 2024	n/a	n/a	€32m
Mar 31 2024	n/a	n/a	€31m
Dec 31 2023	€2m	€750k	-€4m
Sep 30 2023	n/a	n/a	-€153m
Jun 30 2023	n/a	n/a	-€46m
Mar 31 2023	n/a	n/a	-€69m
Dec 31 2022	€1m	€563k	-€71m

報酬と市場: Paulの総報酬 ($USD 2.08M ) は、 UK市場 ($USD 2.31M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Paulの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Paul Stoffels (62 yo)

2.6yrs

在職期間

€1,971,286

報酬

Dr. Paulus A. Stoffels, also known as Paul, Ph.D. M.D. is Chief Executive Officer of Galapagos NV since April 01, 2022 and also serves as its Chairman since April 26, 2022 and also serves as its Interim He...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Paulus Stoffels	CEO, Chairman	2.6yrs	€1.97m	データなし
Thad Huston	Executive VP	1.3yrs	データなし	データなし
Sofie Van Gijsel	Head of Investor Relations	no data	データなし	データなし
Valeria Cnossen	Executive VP & General Counsel	2.8yrs	データなし	データなし
Marieke Vermeersch	Head of Corporate Communication	no data	データなし	データなし
Annelies Missotten	Executive VP & Chief Human Resources Officer	no data	データなし	データなし
Ellen Aar	Head of Development	no data	データなし	データなし
Philippe Alen	Senior VP & Head of Business Development	2.8yrs	データなし	データなし
Alice Dietrich	Head of Medical Affairs	no data	データなし	データなし
Pierre Raboisson	Head of Small Molecules Discovery & Senior VP	2.4yrs	データなし	データなし
Patrik Ringblom	Head of Strategy & US Lead	1.1yrs	データなし	データなし
Jeevan Shetty	Head of Clinical Development Oncology	no data	データなし	データなし

2.5yrs

平均在職期間

52.5yo

平均年齢

経験豊富な経営陣: 0JXZの経営陣は経験豊富であると考えられます ( 2.5年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Paulus Stoffels	CEO, Chairman	2.6yrs	€1.97m	データなし
Simon Sturge	Independent Non-Executive Director	1.2yrs	€32.37k	0.00027% € 4.7k
Jerome Contamine	Lead Independent Non-Executive Director	2.6yrs	€150.00k	0.0015% € 26.4k
Andrew Dickinson	Non-Executive Non-Independent Director	less than a year	データなし	データなし
Linda Higgins	Non-Executive Non-Independent Director	5.1yrs	データなし	データなし
Susanne Schaffert	Non-Executive Independent Director	1.4yrs	€59.85k	0.00055% € 9.5k
Oleg Nodelman	Non-Executive Non-Independent Director	less than a year	データなし	データなし
Peter Guenter	Independent Non-Executive Director	5.6yrs	€115.00k	0.0030% € 52.0k
Elisabeth Svanberg	Independent Non-Executive Director	4.6yrs	€138.75k	0.0029% € 49.3k

2.6yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: 0JXZの取締役会は経験豊富ではない ( 2.6年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Galapagos マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Galapagos NV Announces Board Changes

Galapagos NV Announces Board Changes

Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos

High number of new directors

Galapagos NV Announces Board Changes

Galapagos Appoints Thad Huston as Chief Financial Officer, Effective from July 1, 2023

Recent updates

Forecast to breakeven in 2024

Third quarter 2024 earnings released: €0.74 loss per share (vs €0.39 profit in 3Q 2023)

Galapagos NV to Report First Half, 2025 Results on Jul 23, 2025

Galapagos NV Announces Board Changes

Investor sentiment improves as stock rises 16%

Galapagos Announces FDA Clearance of IND Application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in Relapsed/Refractory Non-Hodgkin Lymphoma

Second quarter 2024 earnings released

Galapagos NV to Report Fiscal Year 2024 Results on Feb 12, 2025

First quarter 2024 earnings released: EPS: €0.36 (vs €0.35 in 1Q 2023)

Full year 2023 earnings released: €0.061 loss per share (vs €1.09 loss in FY 2022)

Galapagos NV Announces Board Changes

Full year 2023 earnings released: €0.06 loss per share (vs €3.32 loss in FY 2022)

Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024

Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV (ENXTAM:GLPG).

Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos

Galapagos Announces Start of PAPILIO-1 Phase 1/2 Multiple Myeloma Study of Point-Of-Care Manufactured BCMA CAR-T Candidate, GLPG5301

Galapagos Presents New Encouraging Clinical Data from the Ongoing Phase 1/2 CD19 CAR-T Studies with GLPG5201 and GLPG5101

Galapagos NV to Report First Half, 2024 Results on Aug 01, 2024

Third quarter 2023 earnings released: EPS: €0.39 (vs €0.33 in 3Q 2022)

High number of new directors

Galapagos NV Announces Board Changes

Galapagos NV to Report Q4, 2023 Results on Mar 28, 2024

Galapagos NV Announces Start of Phase 2 Study with Selective Tyk2 Inhibitor, GLPG3667, in Patients with Active Systemic Lupus Erythematosus

New major risk - Revenue and earnings growth

Galapagos NV Revises Sales Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: €0.078 (vs €0.29 loss in 2Q 2022)

Galapagos Appoints Thad Huston as Chief Financial Officer, Effective from July 1, 2023

Galapagos NV Announces Director Changes

Galapagos to Showcase CAR-T Point-Of-Care Manufacturing and Initial Phase 1/2 CLL Data with CD19 CAR-T Candidate, GLPG5201, at the EHA 2023 Congress

First quarter 2023 earnings released: EPS: €0.35 (vs €0.20 loss in 1Q 2022)

Full year 2022 earnings released: €3.32 loss per share (vs €1.92 loss in FY 2021)

Full year 2022 earnings released: €3.32 loss per share (vs €1.92 loss in FY 2021)

Galapagos NV Announces Topline Results from Phase 3 DIVERSITY Trial of Filgotinib in Crohn’s Disease

Galapagos NV Announces Changes in the Executive Committee Effective 1 January 2023

Galapagos and CellPoint Presented Encouraging Initial Data AtASH 2022 for GLPG5101, a CD19 CAR-T Candidate Manufactured At Point-Of-Care

Galapagos Announces CHMP Adoption of PRAC’s Recommendation for Jyseleca® Following Extensive Safety Review of all JAK Inhibitors

Galapagos NV to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

Galapagos NV to Report Fiscal Year 2022 Final Results on Mar 23, 2023

Third quarter 2022 earnings released: EPS: €0.30 (vs €0.99 loss in 3Q 2021)

Galapagos NV to Report Q1, 2023 Results on May 04, 2023

Galapagos Receives Positive CHMP Opinion for Jyseleca® European Label Update Based on Testicular Function Safety Data from MANTA/RAy Studies

Galapagos NV announced that it has received €3.07625 million in funding

Galapagos NV Revises Revenue Guidance of Jyseleca for the Full Year 2022

Second quarter 2022 earnings released: €0.29 loss per share (vs €0.98 loss in 2Q 2021)

Galapagos NV (ENXTAM:GLPG) entered into a definitive agreement to acquire Abound Bio, Inc. for $14 million.

Galapagos NV announced that it expects to receive €1.459507 million in funding

High number of new directors

First quarter 2022 earnings released: €0.20 loss per share (vs €0.20 loss in 1Q 2021)

Galapagos NV to Report Q3, 2022 Results on Nov 03, 2022

Galapagos NV Announces Executive Appointments

Galapagos NV Announces Approval of Additional Indication Based on Phase 2B/3 SELECTION Study in Patients with Moderate-To-Severe Ulcerative Colitis

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Galapagos Provides Further Insights into the Treatment of Ulcerative Colitis At the European Crohn’s and Colitis Organization Annual Congress

Galapagos NV Announces Authorization of Medicines and Healthcare Products Regulatory Agency for Jyseleca (Filgotinib), as New Treatment for Ulcerative Colitis in Great Britain

Galapagos Nv Completes Patient Recruitment for Mangrove Phase 2 Trial with GLPG2737 in Polycystic Kidney Disease

Third quarter 2021 earnings released: €0.64 loss per share (vs €1.25 loss in 3Q 2020)

Galapagos Announces Positive CHMP Opinion for Jyseleca® (Filgotinib) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Second quarter 2021 earnings released: €0.98 loss per share (vs €1.80 loss in 2Q 2020)

Galapagos NV Demonstrates Early Clinical Activity with SIK2/3 Inhibition in Inflammation

Galapagos NV Announces That Primary and Secondary Endpoint Results from the Phase 3 SELECTIONinduction

Galapagos NV to Present Data on Rheumatoid Arthritis At the Upcoming European League Against Rheumatism (EULAR) Congress

Galapagos Announces First Patient Enrolled in FILOSOPHY Study to Advance Understanding of Jyseleca (Filgotinib) Effectiveness and Safety in A Real-World Setting

Galapagos Reports Primary Endpoint for the Ongoing Filgotinib MANTA and MANTA-RAy Safety Studies

Revenue beats expectations

Galapagos NV to Report Fiscal Year 2020 Final Results on Mar 25, 2021

Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF

New 90-day low: €73.62

Galapagos NV to Report Fiscal Year 2021 Results on Feb 24, 2022

NICE Recommends Galapagos Jyseleca (Filgotinib) on NHS in Decision for Rheumatoid Arthritis

マネジメント基準チェック /24